Search

Your search keyword '"Casanova, Michela"' showing total 1,159 results
Start Over Author "Casanova, Michela"
1,159 results on '"Casanova, Michela"'

103. Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin’s Lymphoma in Children

Author

Schiavello, Elisabetta, primary, Spreafico, Filippo, additional, Barretta, Francesco, additional, Meraviglia, Giulia, additional, Biassoni, Veronica, additional, Terenziani, Monica, additional, Boschetti, Luna, additional, Gattuso, Giovanna, additional, Chiaravalli, Stefano, additional, Bergamaschi, Luca, additional, Puma, Nadia, additional, Sironi, Giovanna, additional, Nigro, Olga, additional, Podda, Marta, additional, Meazza, Cristina, additional, Casanova, Michela, additional, Ferrari, Andrea, additional, Luksch, Roberto, additional, and Massimino, Maura, additional

Published
2022
Full Text
View/download PDF

104. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study

Author

Ferrari, Andrea, primary, Chisholm, Julia C, additional, Jenney, Meriel, additional, Minard-Colin, Veronique, additional, Orbach, Daniel, additional, Casanova, Michela, additional, Guillen, Gabriela, additional, Glosli, Heidi, additional, van Rijn, Rick R, additional, Schoot, Reineke A, additional, Cameron, Alison L, additional, Rogers, Timothy, additional, Alaggio, Rita, additional, Ben-Arush, Myriam, additional, Mandeville, Henry C, additional, Devalck, Christine, additional, Defachelles, Anne-Sophie, additional, Coppadoro, Beatrice, additional, Bisogno, Gianni, additional, and Merks, Johannes H M, additional

Published
2022
Full Text
View/download PDF

105. Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Author

Orbach, Daniel, primary, Van Noesel, Max M., additional, Brennan, Bernadette, additional, Corradini, Nadège, additional, Alaggio, Rita, additional, Ben Arush, Myriam, additional, Schoot, Reineke A., additional, Berlanga, Pablo, additional, Zanetti, Ilaria, additional, Hjalgrim, Lisa Lyngsie, additional, Di Corti, Federica, additional, Ramirez, Gema, additional, Casanova, Michela, additional, and Ferrari, Andrea, additional

Published
2022
Full Text
View/download PDF

106. Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse

Author

Chiaravalli, Stefano, primary, Bergamaschi, Luca, additional, Livellara, Virginia, additional, Sironi, Giovanna, additional, Puma, Nadia, additional, Nigro, Olga, additional, Gattuso, Giovanna, additional, Luksch, Roberto, additional, Terenziani, Monica, additional, Spreafico, Filippo, additional, Meazza, Cristina, additional, Podda, Marta, additional, Biassoni, Veronica, additional, Schiavello, Elisabetta, additional, Morosi, Carlo, additional, Massimino, Maura, additional, Casanova, Michela, additional, and Ferrari, Andrea, additional

Published
2022
Full Text
View/download PDF

107. Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single‐center experience

Author

Ferrari, Andrea, primary, Bergamaschi, Luca, additional, Chiaravalli, Stefano, additional, Livellara, Virginia, additional, Sironi, Giovanna, additional, Nigro, Olga, additional, Puma, Nadia, additional, Gattuso, Giovanna, additional, Morosi, Carlo, additional, Gasparini, Patrizia, additional, Caccavo, Roberta, additional, Pecori, Emilia, additional, Alessandro, Ombretta, additional, Vennarini, Sabina, additional, Gandola, Lorenza, additional, Massimino, Maura, additional, and Casanova, Michela, additional

Published
2022
Full Text
View/download PDF

108. How ten-years of reirradiation for paediatric high-grade glioma can shed light on first line treatment

Author

Massimino, Maura, primary, Vennarini, Sabina, additional, Barretta, Francesco, additional, Colombo, Francesca, additional, Antonelli, Manila, additional, Pollo, Bianca, additional, Pignoli, Emanuele, additional, Pecori, Emilia, additional, Alessandro, Ombretta, additional, Schiavello, Elisabetta, additional, Boschetti, Luna, additional, Podda, Marta, additional, Puma, Nadia, additional, Gattuso, Giovanna, additional, Sironi, Giovanna, additional, Barzanò, Elena, additional, Nigro, Olga, additional, Bergamaschi, Luca, additional, Chiaravalli, Stefano, additional, Luksch, Roberto, additional, Meazza, Cristina, additional, Spreafico, Filippo, additional, Terenziani, Monica, additional, Casanova, Michela, additional, Ferrari, Andrea, additional, Chisari, Marco, additional, Pellegrini, Chiara, additional, Clerici, Carlo Alfredo, additional, Modena, Piergiorgio, additional, and Biassoni, Veronica, additional

Published
2022
Full Text
View/download PDF

109. Update on phase 1 study of tazemetostat, an enhancer of zeste homolog 2 inhibitor, in pediatric patients with relapsed or refractory integrase interactor 1–negative tumors.

Author

Chi, Susan N., primary, Bourdeaut, Franck, additional, Casanova, Michela, additional, Kilburn, Lindsay Baker, additional, Hargrave, Darren R., additional, McCowage, Geoffrey Brian, additional, Pinto, Navin R., additional, Yang, Jay, additional, Chadha, Raminder, additional, Kahali, Bhaskar, additional, Tapia, Coya, additional, and Nysom, Karsten, additional

Published
2022
Full Text
View/download PDF

110. Caring for children with cancer evacuated from Ukraine

Author

Massimino, Maura, primary, Casiraghi, Giovanna, additional, Armiraglio, Mariangela, additional, Cabibbe, Daniele, additional, Luksch, Roberto, additional, Terenziani, Monica, additional, Casanova, Michela, additional, Spreafico, Filippo, additional, Meazza, Cristina, additional, Podda, Marta, additional, Biassoni, Veronica, additional, Schiavello, Elisabetta, additional, Chiaravalli, Stefano, additional, Puma, Nadia, additional, Bergamaschi, Luca, additional, Gattuso, Giovanna, additional, Sironi, Giovanna, additional, Nigro, Olga, additional, Livellara, Virginia, additional, Hovsepyan, Shushan, additional, Ferrari, Andrea, additional, and Clerici, Carlo Alfredo, additional

Published
2022
Full Text
View/download PDF

111. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Author

Waguespack, Steven G, primary, Drilon, Alexander, additional, Lin, Jessica J, additional, Brose, Marcia S, additional, McDermott, Ray, additional, Almubarak, Mohammed, additional, Bauman, Jessica, additional, Casanova, Michela, additional, Krishnamurthy, Anuradha, additional, Kummar, Shivaani, additional, Leyvraz, Serge, additional, Oh, Do-Youn, additional, Park, Keunchil, additional, Sohal, Davendra, additional, Sherman, Eric, additional, Norenberg, Ricarda, additional, Silvertown, Josh D, additional, Brega, Nicoletta, additional, Hong, David S, additional, and Cabanillas, Maria E, additional

Published
2022
Full Text
View/download PDF

112. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study

Author

Zsiros, József, Brugieres, Laurence, Brock, Penelope, Roebuck, Derek, Maibach, Rudolf, Zimmermann, Arthur, Childs, Margaret, Pariente, Daniele, Laithier, Veronique, Otte, Jean-Bernard, Branchereau, Sophie, Aronson, Daniel, Rangaswami, Arun, Ronghe, Milind, Casanova, Michela, Sullivan, Michael, Morland, Bruce, Czauderna, Piotr, and Perilongo, Giorgio

Published
2013
Full Text
View/download PDF

113. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults

Author

Sparber-Sauer, Monika, Ferrari, Andrea, Kosztyla, Daniel, Ladenstein, Ruth, Cecchetto, Giovanni, Kazanowska, Bernarda, Scarzello, Giovanni, Ljungman, Gustaf, Milano, Giuseppe Maria, Niggli, Felix, Alaggio, Rita, Vokuhl, Christian, Casanova, Michela, Klingebiel, Thomas, Zin, Angelica, Koscielniak, Ewa, Bisogno, Gianni, Sparber-Sauer, Monika, Ferrari, Andrea, Kosztyla, Daniel, Ladenstein, Ruth, Cecchetto, Giovanni, Kazanowska, Bernarda, Scarzello, Giovanni, Ljungman, Gustaf, Milano, Giuseppe Maria, Niggli, Felix, Alaggio, Rita, Vokuhl, Christian, Casanova, Michela, Klingebiel, Thomas, Zin, Angelica, Koscielniak, Ewa, and Bisogno, Gianni

Abstract

Background: CWS/RMS-96 was an international multicenter trial with randomization between two therapy arms of the standard four-drug therapy (vincristine, ifosfamide, adriamycin, dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) for high-risk rhabdomyosarcoma (RMS), extraskeletal Ewing sarcoma (EES), and undifferentiated sarcoma (UDS) in children, adolescents, and young adults aiming to improve their survival. Intensified chemotherapy with CEVAIE did not improve outcome. Methods: Patients younger than 21 years with a previously untreated localized HR-RMS, EES, and UDS were enrolled from Cooperative Weichteilsarkom Studiengruppe (CWS) centers in Germany, Austria, Poland, Switzerland, and from Italian Soft Tissue Sarcoma Committee (STSC) centers. Randomization (1:1) to receive either 9 x 21 days cycles of VAIA or CEVAIE was performed separately in CWS and STSC. Hyperfractionated accelerated radiotherapy (32-44.8 Gy) was added at week 9-12 according to histology and response to chemotherapy. A secondary microscopically complete nonmutilating resection was performed if possible. Primary endpoints were response to chemotherapy, event-free (EFS) and overall survival (OS). Results: Five hundred fifty-seven patients (HR-RMS: n = 416, EES and UDS: n = 141) underwent randomization: VAIA (n = 273) or CEVAIE (n = 284). Radiotherapy was given to 70% of patients in both groups. A secondary resection was performed in 47% and 48% patients, respectively. The 5-year EFS and OS for the VAIA and CEVAIE treatment arms were 59.8% and 60.8% (p = .89), and 74.2% and 68.3% (p = .16), respectively. No differences in response, toxicity, or second malignancies emerged in the two groups. Conclusion: The use of an intensified regimen failed to show a significant improvement in tumor response and outcome of patients with localized HR-RMS, EES, and UDS.

Published
2022
Full Text
View/download PDF

114. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study

Author

Ferrari, Andrea, Chisholm, Julia, Jenney, Meriel, Minard-Colin, Véronique, Orbach, Daniel, Casanova, Michela, Guillen, Gabriela, Glosli, Heidi, Van Rijn, Rick Robert, Schoot, Reineke R.A., Cameron, Alison, Rogers, Timothy, Alaggio, Rita, Ben-Arush, Myriam, Mandeville, Henry H.C., Devalck, Christine, Defachelles, Anne Sophie, Coppadoro, Beatrice, Bisogno, Gianni, Merks, Johannes H M, Ferrari, Andrea, Chisholm, Julia, Jenney, Meriel, Minard-Colin, Véronique, Orbach, Daniel, Casanova, Michela, Guillen, Gabriela, Glosli, Heidi, Van Rijn, Rick Robert, Schoot, Reineke R.A., Cameron, Alison, Rogers, Timothy, Alaggio, Rita, Ben-Arush, Myriam, Mandeville, Henry H.C., Devalck, Christine, Defachelles, Anne Sophie, Coppadoro, Beatrice, Bisogno, Gianni, and Merks, Johannes H M

Abstract

Background: Adolescent and young adult patients with rhabdomyosarcoma often have poorer outcomes than do children. We aimed to compare the findings of adolescent and young adult patients with children enrolled in two prospective clinical protocols. Methods: This retrospective observational analysis was based on data from the European paediatric Soft tissue sarcoma Study Group (EpSSG) rhabdomyosarcoma 2005 trial (phase 3 randomised trial for localised rhabdomyosarcoma, open from April, 2006, to December, 2016) and the EpSSG MTS 2008 protocol (prospective, observational, single-arm study for metastatic rhabdomyosarcoma, open from June, 2010, to December, 2016), which involved 108 centres from 14 different countries in total. For this analysis, patients were categorised according to their age into children (age 0–14 years) and adolescents and young adults (age 15–21 years). For the analysis of adherence to treatment and toxicity, only patients with high-risk localised rhabdomyosarcoma included in the randomised part of the rhabdomyosarcoma 2005 study were considered. The primary outcome of event-free survival (assessed in all participants) was defined as the time from diagnosis to the first event (eg, tumour progression, relapse) or to the latest follow-up. Secondary outcomes were overall survival, response to chemotherapy, and toxicity. Findings: Our analysis included 1977 patients, 1720 children (median age 4·7 years; IQR 2·6–8·4) and 257 adolescents and young adults (16·6 years; 15·8–18·0). 1719 patients were from the EpSSG rhabdomyosarcoma 2005 study (1523 aged <15 years and 196 aged 15–21 years) and 258 patients were from the EPSSG MTS 2008 study (197 aged <15 years and 61 aged 15–21 years). Adolescent and young adult patients were more likely than were children to have metastatic tumours (61 [23·7%] of 257 vs 197 [11·5%] of 1720; p<0·0001), unfavourable histological subtypes (119 [46·3%] vs 451 [26·2%]; p<0·0001), tumours larger than 5 cm (177 [68·9%] vs 891 [51·, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

115. Shedding a Light on the Challenges of Adolescents and Young Adults with Rhabdomyosarcoma

Author

Ferrari, Andrea, Gatz, Susanne Andrea, Minard-Colin, Veronique, Alaggio, Rita, Hovsepyan, Shushan, Orbach, Daniel, Gasparini, Patrizia, Defachelles, Anne Sophie, Casanova, Michela, Milano, Giuseppe Maria, Chisholm, Julia C., Jenney, Meriel, Bisogno, Gianni, Rogers, Timothy, Mandeville, Henry C., Shipley, Janet, Miah, Aisha B., Merks, Johannes H.M., van der Graaf, Winette T.A., Ferrari, Andrea, Gatz, Susanne Andrea, Minard-Colin, Veronique, Alaggio, Rita, Hovsepyan, Shushan, Orbach, Daniel, Gasparini, Patrizia, Defachelles, Anne Sophie, Casanova, Michela, Milano, Giuseppe Maria, Chisholm, Julia C., Jenney, Meriel, Bisogno, Gianni, Rogers, Timothy, Mandeville, Henry C., Shipley, Janet, Miah, Aisha B., Merks, Johannes H.M., and van der Graaf, Winette T.A.

Abstract

Rhabdomyosarcoma (RMS) is a typical tumour of childhood but can occur at any age. Several studies have reported that adolescent and young adult (AYA) patients with RMS have poorer survival than do younger patients. This review discusses the specific challenges in AYA patients with pediatric-type RMS, exploring possible underlying factors which may influence different outcomes. Reasons for AYA survival gap are likely multifactorial, and might be related to differences in tumor biology and intrinsic aggressiveness, or differences in clinical management (that could include patient referral patterns, time to diagnosis, enrolment into clinical trials, the adequacy and intensity of treatment), as well as patient factors (including physiology and comorbidity that may influence treatment tolerability, drug pharmacokinetics and efficacy). However, improved survival has been reported in the most recent studies for AYA patients treated on pediatric RMS protocols. Different strategies may help to further improve outcome, such as supporting trans-age academic societies and national/international collaborations; developing specific clinical trials without upper age limit; defining integrated and comprehensive approach to AYA patients, including the genomic aspects; establishing multidisciplinary tumor boards with involvement of both pediatric and adult oncologists to discuss all pediatric-type RMS patients; developing dedicated projects with specific treatment recommendations and registry/database.

Published
2022

116. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Author

Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, Cabanillas, Maria E, Waguespack, Steven G, Drilon, Alexander, Lin, Jessica J, Brose, Marcia S, McDermott, Ray, Almubarak, Mohammed, Bauman, Jessica, Casanova, Michela, Krishnamurthy, Anuradha, Kummar, Shivaani, Leyvraz, Serge, Oh, Do-Youn, Park, Keunchil, Sohal, Davendra, Sherman, Eric, Norenberg, Ricarda, Silvertown, Josh D, Brega, Nicoletta, Hong, David S, and Cabanillas, Maria E

Abstract

Objective: Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC). Methods: We pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Data cut-off: July 2020. Results: Twenty-nine patients (median age: 60; range: 6-80) with TRK fusion-positive TC were treated. Tumour histology was papillary (PTC) in 20 (69%) patients, follicular (FTC) in 2 (7%), and anaplastic (ATC) in 7 (24%) patients. Among 28 evaluable patients, ORR was 71% (95% CI: 51-87); best responses were complete response in 2 (7%) patients, partial response in 18 (64%), stable disease in 4 (14%), progressive disease in 3 (11%), and undetermined in 1 (4%) due to clinical progression prior to the first post-baseline assessment. ORR was 86% (95% CI: 64-97) for PTC/FTC and 29% (95% CI 4-71) for ATC. Median time to response was 1.87 months (range 1.64-3.68). The 24-month DoR, PFS, and OS rates were 81, 69, and 76%, respectively. Treatment-related adverse events were mainly grades 1-2. Conclusion: In TRK fusion-positive TC, larotrectinib demonstrates rapid and durable disease control and a favourable safety profile in patients with advanced disease requiring systemic therapy. Significance statement: NTRK gene fusions are known oncogenic drivers and have been identified in various histologies of thyroid carcinoma, most commonly in papillary thyroid carcinoma. This is the first publication specifically studying a TRK inhibitor in a cohort of TRK fusion-positive thyroid carcinoma patients. In th

Published
2022

117. Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas: Standard of Care and Treatment Recommendations from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG)

Author

Arts-assistenten Kinderen, Onderzoek Beeld, Cancer, Ferrari, Andrea, Brennan, Bernadette, Casanova, Michela, Corradini, Nadege, Berlanga, Pablo, Schoot, Reineke A., Ramirez-Villar, Gema L., Safwat, Akmal, Burrieza, Gabriela Guillen, Dall’igna, Patrizia, Alaggio, Rita, Hjalgrim, Lisa Lyngsie, Gatz, Susanne Andrea, Orbach, Daniel, van Noesel, Max M., Arts-assistenten Kinderen, Onderzoek Beeld, Cancer, Ferrari, Andrea, Brennan, Bernadette, Casanova, Michela, Corradini, Nadege, Berlanga, Pablo, Schoot, Reineke A., Ramirez-Villar, Gema L., Safwat, Akmal, Burrieza, Gabriela Guillen, Dall’igna, Patrizia, Alaggio, Rita, Hjalgrim, Lisa Lyngsie, Gatz, Susanne Andrea, Orbach, Daniel, and van Noesel, Max M.

Published
2022

118. Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Author

Onderzoek Beeld, Arts-assistenten Kinderen, Orbach, Daniel, Van Noesel, Max M, Brennan, Bernadette, Corradini, Nadège, Alaggio, Rita, Ben Arush, Myriam, Schoot, Reineke A, Berlanga, Pablo, Zanetti, Ilaria, Hjalgrim, Lisa Lyngsie, Di Corti, Federica, Ramirez, Gema, Casanova, Michela, Ferrari, Andrea, Onderzoek Beeld, Arts-assistenten Kinderen, Orbach, Daniel, Van Noesel, Max M, Brennan, Bernadette, Corradini, Nadège, Alaggio, Rita, Ben Arush, Myriam, Schoot, Reineke A, Berlanga, Pablo, Zanetti, Ilaria, Hjalgrim, Lisa Lyngsie, Di Corti, Federica, Ramirez, Gema, Casanova, Michela, and Ferrari, Andrea

Published
2022

124. Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases

Author

Ferrari, Andrea, primary, Chiaravalli, Stefano, additional, Bergamaschi, Luca, additional, Nigro, Olga, additional, Livellara, Virginia, additional, Sironi, Giovanna, additional, Gasparini, Patrizia, additional, Pasquali, Sandro, additional, Zaffaroni, Nadia, additional, Stacchiotti, Silvia, additional, Morosi, Carlo, additional, Massimino, Maura, additional, and Casanova, Michela, additional

Published
2022
Full Text
View/download PDF

125. Long‐term results from the multicentric European randomized phase 3 trial CWS/RMS‐96 for localized high‐risk soft tissue sarcoma in children, adolescents, and young adults

Author

Sparber‐Sauer, Monika, primary, Ferrari, Andrea, additional, Kosztyla, Daniel, additional, Ladenstein, Ruth, additional, Cecchetto, Giovanni, additional, Kazanowska, Bernarda, additional, Scarzello, Giovanni, additional, Ljungman, Gustaf, additional, Milano, Giuseppe Maria, additional, Niggli, Felix, additional, Alaggio, Rita, additional, Vokuhl, Christian, additional, Casanova, Michela, additional, Klingebiel, Thomas, additional, Zin, Angelica, additional, Koscielniak, Ewa, additional, and Bisogno, Gianni, additional

Published
2022
Full Text
View/download PDF

126. Managing Care during the COVID-19 Pandemic: The Point of View and Fears of Pediatric Cancer Patients’ Families

Author

Nigro, Olga, primary, Sironi, Giovanna, additional, Ferrari, Andrea, additional, Tinè, Gabriele, additional, Infante, Gabriele, additional, Barretta, Francesco, additional, Silva, Matteo, additional, Clerici, Carlo Alfredo, additional, Chiaravalli, Stefano, additional, Schiavello, Elisabetta, additional, Biassoni, Veronica, additional, Podda, Marta, additional, Meazza, Cristina, additional, Spreafico, Filippo, additional, Casanova, Michela, additional, Terenziani, Monica, additional, Luksch, Roberto, additional, and Massimino, Maura, additional

Published
2022
Full Text
View/download PDF

127. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

Author

Berlanga, Pablo, primary, Pierron, Gaelle, additional, Lacroix, Ludovic, additional, Chicard, Mathieu, additional, Adam de Beaumais, Tiphaine, additional, Marchais, Antonin, additional, Harttrampf, Anne C., additional, Iddir, Yasmine, additional, Larive, Alicia, additional, Soriano Fernandez, Aroa, additional, Hezam, Imene, additional, Chevassus, Cecile, additional, Bernard, Virginie, additional, Cotteret, Sophie, additional, Scoazec, Jean-Yves, additional, Gauthier, Arnaud, additional, Abbou, Samuel, additional, Corradini, Nadege, additional, André, Nicolas, additional, Aerts, Isabelle, additional, Thebaud, Estelle, additional, Casanova, Michela, additional, Owens, Cormac, additional, Hladun-Alvaro, Raquel, additional, Michiels, Stefan, additional, Delattre, Olivier, additional, Vassal, Gilles, additional, Schleiermacher, Gudrun, additional, and Geoerger, Birgit, additional

Published
2022
Full Text
View/download PDF

129. sj-pdf-1-tmj-10.1177_03008916221110266 – Supplemental material for Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics

Author

Gasparini, Patrizia, Casanova, Michela, Centonze, Giovanni, Borzi, Cristina, Bergamaschi, Luca, Collini, Paola, Testi, Adele, Chiaravalli, Stefano, Massimino, Maura, Sozzi, Gabriella, Ferrari, Andrea, and Moro, Massimo

Subjects
Medicine
Abstract

Supplemental material, sj-pdf-1-tmj-10.1177_03008916221110266 for Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics by Patrizia Gasparini, Michela Casanova, Giovanni Centonze, Cristina Borzi, Luca Bergamaschi, Paola Collini, Adele Testi, Stefano Chiaravalli, Maura Massimino, Gabriella Sozzi, Andrea Ferrari and Massimo Moro in Tumori Journal

Published
2022
Full Text
View/download PDF

130. sj-pdf-2-tmj-10.1177_03008916221110266 – Supplemental material for Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics

Author

Gasparini, Patrizia, Casanova, Michela, Centonze, Giovanni, Borzi, Cristina, Bergamaschi, Luca, Collini, Paola, Testi, Adele, Chiaravalli, Stefano, Massimino, Maura, Sozzi, Gabriella, Ferrari, Andrea, and Moro, Massimo

Subjects
Medicine
Abstract

Supplemental material, sj-pdf-2-tmj-10.1177_03008916221110266 for Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics by Patrizia Gasparini, Michela Casanova, Giovanni Centonze, Cristina Borzi, Luca Bergamaschi, Paola Collini, Adele Testi, Stefano Chiaravalli, Maura Massimino, Gabriella Sozzi, Andrea Ferrari and Massimo Moro in Tumori Journal

Published
2022
Full Text
View/download PDF

131. Correction to: Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood

Author

Massimino, Maura, Biassoni, Veronica, Miceli, Rosalba, Schiavello, Elisabetta, Warmuth-Metz, Monika, Modena, Piergiorgio, Casanova, Michela, Pecori, Emilia, Giangaspero, Felice, Antonelli, Manila, Buttarelli, Francesca Romana, Potepan, Paolo, Pollo, Bianca, Nunziata, Raffaele, Spreafico, Filippo, Podda, Marta, Anichini, Andrea, Clerici, Carlo Alfredo, Sardi, Iacopo, De Cecco, Loris, Bode, Udo, Bach, Ferdinand, and Gandola, Lorenza

Published
2018
Full Text
View/download PDF

132. Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics

Author

Gasparini, Patrizia, Casanova, Michela, Centonze, Giovanni, Borzi, Cristina, Bergamaschi, Luca, Collini, Paola, Testi, Adele, Chiaravalli, Stefano, Massimino, Maura, Sozzi, Gabriella, Ferrari, Andrea, and Moro, Massimo

Abstract

Introduction: The prognosis for patients with metastatic and recurrent pediatric rhabdomyosarcoma (RMS) remains poor. The availability of preclinical models is essential to identify promising treatments We established a series of pediatric RMS patient derived xenografts (PDXs), all faithfully mirroring primary tumor characteristics and representing a unique tool for clarifying the biological processes underlying RMS progression and relapse.Methods: Fresh tumor samples from 12 RMS patients were implanted subcutaneously in both flanks of immunocompromised mice. PDXs were considered as grafted after accomplishing three passages in mice. Characterization of tumor tissues and models was performed by comparing both morphology and immunoistochemical and fluorescence in situ hybridization (FISH) characteristics.Results: Six PDXs were established, with a successful take rate of 50%. All models closely mirrored parental tumor characteristics. An increased grafting rate for tumors derived from patients with worse outcome (p = 0.006) was detected. For 50% PDXs grafting occurred when the corresponding patient was still alive.Conclusion: Our findings increase the number of available RMS PDX models and strengthen the role of PDXs as useful preclinical tools for patients with unmet medical needs and to develop personalized therapies.

Published
2023
Full Text
View/download PDF

133. Reply to H. B et al

Author

Defachelles, Anne-Sophie, primary, Bogart, Emilie, additional, Casanova, Michela, additional, Merks, Johannes H.M., additional, Bisogno, Gianni, additional, Calareso, Giuseppina, additional, Melcon, Soledad Gallego, additional, Gatz, Susanne Andrea, additional, Le Deley, Marie-Cécile, additional, McHugh, Kieran, additional, Probst, Alicia, additional, Rocourt, Nathalie, additional, van Rijn, Rick R., additional, Minard-Colin, Véronique, additional, and Chisholm, Julia C., additional

Published
2022
Full Text
View/download PDF

135. Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?

Author

Gattuso, Giovanna, primary, Schiavello, Elisabetta, additional, Oltolini, Chiara, additional, Biassoni, Veronica, additional, Terenziani, Monica, additional, Chiaravalli, Stefano, additional, Podda, Marta Giorgia, additional, Meazza, Cristina, additional, Luksch, Roberto, additional, Ferrari, Andrea, additional, Casanova, Michela, additional, Sironi, Giovanna, additional, Bergamaschi, Luca, additional, Puma, Nadia, additional, Spreafico, Filippo, additional, and Massimino, Maura, additional

Published
2021
Full Text
View/download PDF

136. Extraosseous Ewing sarcoma in children and adolescents: A retrospective series from a referral pediatric oncology center

Author

Livellara, Virginia, primary, Bergamaschi, Luca, additional, Puma, Nadia, additional, Chiaravalli, Stefano, additional, Podda, Marta, additional, Casanova, Michela, additional, Gasparini, Patrizia, additional, Pecori, Emilia, additional, Alessandro, Ombretta, additional, Nigro, Olga, additional, Sironi, Giovanna, additional, Gattuso, Giovanna, additional, Terenziani, Monica, additional, Spreafico, Filippo, additional, Meazza, Cristina, additional, Biassoni, Veronica, additional, Schiavello, Elisabetta, additional, Massimino, Maura, additional, Luksch, Roberto, additional, and Ferrari, Andrea, additional

Published
2021
Full Text
View/download PDF

138. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood

Author

Massimino, Maura, Biassoni, Veronica, Miceli, Rosalba, Schiavello, Elisabetta, Warmuth-Metz, Monika, Modena, Piergiorgio, Casanova, Michela, Pecori, Emilia, Giangaspero, Felice, Antonelli, Manila, Buttarelli, Francesca Romana, Potepan, Paolo, Pollo, Bianca, Nunziata, Raffaele, Spreafico, Filippo, Podda, Marta, Anichini, Andrea, Clerici, Carlo Alfredo, Sardi, Iacopo, De Cecco, Loris, Bode, Udo, Bach, Ferdinand, and Gandola, Lorenza

Published
2014
Full Text
View/download PDF

141. The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study

Author

Ferrari, Andrea, Lo Vullo, Salvatore, Giardiello, Daniele, Veneroni, Laura, Magni, Chiara, Clerici, Carlo Alfredo, Chiaravalli, Stefano, Casanova, Michela, Luksch, Roberto, Terenziani, Monica, Spreafico, Filippo, Meazza, Cristina, Catania, Serena, Schiavello, Elisabetta, Biassoni, Veronica, Podda, Marta, Bergamaschi, Luca, Puma, Nadia, Massimino, Maura, and Mariani, Luigi

Published
2016
Full Text
View/download PDF

145. Relapse after non‐metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post‐relapse survival.

Author

Casanova, Michela, Bergamaschi, Luca, Chiaravalli, Stefano, Morosi, Carlo, Livellara, Virginia, Hovsepyan, Shushan, Sironi, Giovanna, Puma, Nadia, Nigro, Olga, Gattuso, Giovanna, Luksch, Roberto, Terenziani, Monica, Spreafico, Filippo, Meazza, Cristina, Podda, Marta, Biassoni, Veronica, Schiavello, Elisabetta, Gasparini, Patrizia, Vennarini, Sabina, and Massimino, Maura

Published
2023
Full Text
View/download PDF

146. Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables.

Author

Bergamaschi, Luca, Chiaravalli, Stefano, Livellara, Virginia, Sironi, Giovanna, Puma, Nadia, Nigro, Olga, Gattuso, Giovanna, Luksch, Roberto, Terenziani, Monica, Spreafico, Filippo, Meazza, Cristina, Podda, Marta, Biassoni, Veronica, Schiavello, Elisabetta, Hovsepyan, Shushan, Morosi, Carlo, Vennarini, Sabina, Massimino, Maura, Casanova, Michela, and Ferrari, Andrea

Published
2023
Full Text
View/download PDF

148. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

Author

Pearson, Andrew D.J., primary, Barry, Elly, additional, Mossé, Yael P., additional, Ligas, Franca, additional, Bird, Nick, additional, de Rojas, Teresa, additional, Zimmerman, Zachary F., additional, Wilner, Keith, additional, Woessmann, Willi, additional, Weiner, Susan, additional, Weigel, Brenda, additional, Venkatramani, Rajkumar, additional, Valteau, Dominique, additional, Trahair, Toby, additional, Smith, Malcolm, additional, Singh, Sonia, additional, Selvaggi, Giovanni, additional, Scobie, Nicole, additional, Schleiermacher, Gudrun, additional, Richardson, Nicholas, additional, Park, Julie, additional, Nysom, Karsten, additional, Norga, Koen, additional, Merino, Margret, additional, McDonough, Joe, additional, Matloub, Yousif, additional, Marshall, Lynley V., additional, Lowe, Eric, additional, Lesa, Giovanni, additional, Irwin, Meredith, additional, Karres, Dominik, additional, Gajjar, Amar, additional, Doz, François, additional, Fox, Elizabeth, additional, DuBois, Steven G., additional, Donoghue, Martha, additional, Casanova, Michela, additional, Caron, Hubert, additional, Buenger, Vickie, additional, Bradford, Diana, additional, Blanc, Patricia, additional, Barone, Amy, additional, Reaman, Gregory, additional, and Vassal, Gilles, additional

Published
2021
Full Text
View/download PDF

149. Langerhans cell histiocytosis in adults: a retrospective, single-center case series

Author

Chiaravalli, Stefano, primary, Ferrari, Andrea, additional, Bergamaschi, Luca, additional, Puma, Nadia, additional, Gattuso, Giovanna, additional, Sironi, Giovanna, additional, Nigro, Olga, additional, Livellara, Virginia, additional, Schiavello, Elisabetta, additional, Biassoni, Veronica, additional, Podda, Marta, additional, Meazza, Cristina, additional, Spreafico, Filippo, additional, Casanova, Michela, additional, Terenziani, Monica, additional, Luksch, Roberto, additional, and Massimino, Maura, additional

Published
2021
Full Text
View/download PDF

150. Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma

Author

Varlet, Pascale, primary, Bouffet, Eric, additional, Casanova, Michela, additional, Giangaspero, Felice, additional, Antonelli, Manila, additional, Hargrave, Darren, additional, Ladenstein, Ruth, additional, Pearson, Andy, additional, Hawkins, Cynthia, additional, König, Fatima Barbara, additional, Rüschoff, Josef, additional, Schmauch, Christian, additional, Bühnemann, Claudia, additional, Garin‐Chesa, Pilar, additional, Schweifer, Norbert, additional, Uttenreuther‐Fischer, Martina, additional, Gibson, Neil, additional, Ittrich, Carina, additional, Krämer, Nicole, additional, Solca, Flavio, additional, Stolze, Britta, additional, and Geoerger, Birgit, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results